Marketing a regulated HealthTech product without breaking compliance

Know exactly what your clearance or marking does and does not let you say

An FDA 510(k) clearance, a De Novo authorisation and CE marking under the Medical Device Regulation each define a specific intended use, and your marketing claims are legally bound to that intended use. If your device is cleared for a specific patient population, a specific indication or a specific clinical setting, you cannot market it for a broader use case without triggering off-label promotion exposure, regardless of what the technology is technically capable of.

This is the single most common compliance failure in HealthTech marketing: a product team ships a feature, a marketing team writes a case study describing the outcome in language that implies a broader or different intended use than the clearance covers, and the company is now promoting off-label. Build a one-page claims matrix, reviewed by regulatory counsel, that lists exactly what can and cannot be claimed, and require every piece of external content to be checked against it.

Separate wellness claims from clinical claims, deliberately

Many digital health products deliberately position as wellness or clinical decision support tools specifically to avoid the regulatory burden of a medical device claim. That positioning only holds if your marketing language holds too. The moment a landing page, a sales deck or a customer testimonial claims to diagnose, treat, cure or prevent a specific disease, you may have stepped over the line the regulatory strategy was built to avoid, and unwound years of careful positioning in a single blog post.

This requires marketing and regulatory to sit in the same room, not adjacent silos. The regulatory strategy should define the marketing vocabulary, not the other way around.

Build a med-legal review workflow that does not kill your velocity

The instinct in a growth-stage company is to route every piece of content through legal and watch the content calendar grind to a halt. The better model, used by mature medical device and pharma marketing teams, is tiered review: pre-approved claims language and templates that do not need re-review, a fast lane for content that reuses approved claims, and a full review lane reserved for new claims, new indications or anything referencing clinical data.

Build your claims library once, get it approved once, and your marketing team can move quickly inside it. The bottleneck disappears when the guardrails are clear rather than case-by-case.

• A one-page claims matrix approved by regulatory counsel, refreshed on every clearance update
• Tiered review: pre-approved language, fast lane, full review lane
• A record of every approved claim's clearance basis, kept alongside the marketing asset
• Named sign-off owner for anything referencing clinical outcomes, not a rotating committee

The channels that carry the most hidden risk

Paid social and search platforms increasingly run their own health claims review on top of regulatory law, and healthcare advertisers get flagged or suspended for claims that would pass legal review but violate platform policy. Testimonials and case studies carry particular risk because a customer describing their own experience in their own words can inadvertently make a claim your clearance does not support, and you are responsible for content you publish even if you did not write the words.

KOL and physician partnerships require their own disclosure discipline. Any paid relationship with a physician who appears in your marketing needs a clear financial disclosure, both because it is good practice and because omitting it creates exposure under Sunshine Act reporting requirements in the US and equivalent transparency rules elsewhere.